news
EIDD-2801 shows efficacy against COVID-19 in human cells and mice
Collaborators have shown that the broad spectrum oral antiviral EIDD-2801 could be a potential prophylactic or therapeutic for COVID-19 and other coronaviruses.
List view / Grid view
Therapeutics
news
Researchers reveal how SARS antibody binds to COVID-19 coronavirus
The interaction between a SARS antibody called CR3022 and the COVID-19 coronavirus has been mapped by researchers, revealing a viral vulnerability.
news
Celltrion to select lead antibody candidates to fight COVID-19
Following the screening of antibodies, Celltrion will now identify the most potent out of 300 hits that work against the COVID-19 coronavirus best.
news
Collaboration to develop inhaled mRNA-based antibody therapy for COVID-19
Two companies, Neurimmune and Ethris, will leverage their technologies to research, develop and produce an inhaled therapy for COVID-19.
news
Ivermectin shows activity against COVID-19 in cell cultures
A study has demonstrated that the anti-parasitic drug ivermectin may be effective against SARS-CoV-2, the virus which causes COVID-19.
news
Decoy ACE2 receptors could be promising COVID-19 infection-preventing drug
Recombinant angiotensin converting enzymes (ACE2) reduced infection and viral growth in cell cultures and organoids by acting as a decoy for SARS-CoV-2.
news
AI technology to screen existing drugs for use against COVID-19
A collaboration aims to utilise a compound library of 15,000 clinically-ready molecules and screen then against three COVID-19 targets.
news
COVID-19 update: funding for treatments and vaccines
Drug Target Review rounds up the latest announcements regarding funding for research into COVID-19 treatments and vaccines.
news
Nafamostat inhibits SARS-CoV-2 infection, preventing COVID-19 transmission
Researchers have demonstrated that Nafamostat mesylate (Fusan) can inhibit SARS-CoV-2 Spike protein-initiated membrane fusion at concentrations likely achievable and safe in patients.
news
Novel antiviral compound proposed as COVID-19 therapeutic
A molecule called BOLD-100, developed to fight cancer, has been suggested as a therapeutic to combat the COVID-19 coronavirus due to its antiviral properties.
news
FDA and BARDA to collaborate with Grifols on COVID-19 therapeutics
Grifols will leverage their resources to develop and test convalescent plasma-derived COVID-19 therapeutics in partnership with the FDA and BARDA.
news
Remdesivir most promising COVID-19 drug, say researchers
A review of potential COVID-19 therapeutics revealed that the most effective are likely to be those directly targeting SARS-CoV-2, such as remdesivir and tilarone.
news
Collaboration initiated to develop COVID-19 immunotherapy
The University of Georgia and CEL-SCI Corporation have partnered to develop an immunotherapy to combat the COVID-19 coronavirus using the Ligand Antigen Epitope Presentation System (LEAPS) technology.
news
Map of COVID-19 and human protein interactions reveals drug targets
Researchers have identified which SARS-CoV-2 proteins physically associate with proteins in human cells, revealing potential drug targets to treat the COVID-19 coronavirus.
news
Researchers to screen compound library for antiviral drugs to combat COVID-19
Scripps Research has announced it will screen over 14,000 compounds to see if any present significant activity against COVID-19, for use in a therapeutic.
